BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price objective among […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group in a report issued on Thursday, Benzinga reports. They currently have a $91.00 price objective on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 4.83% from the stock’s current […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities researchers at Canaccord Genuity Group in a report released on Thursday, Benzinga reports. They presently have a $91.00 price objective on the biotechnology company’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 4.83% from the stock’s previous […]
Sherbrooke Park Advisers LLC acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,515 shares of the biotechnology company’s stock, valued at approximately $1,107,000. Other large investors also recently […]
Sherbrooke Park Advisers LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 3rd quarter, Holdings Channel reports. The firm bought 12,515 shares of the biotechnology company’s stock, valued at approximately $1,107,000. A number of other hedge funds have also added to or reduced their stakes in BMRN. […]